Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data by Merriel, SWD et al.
1Merriel SWD, et al. BMJ Open 2021;11:e044420. doi:10.1136/bmjopen-2020-044420
Open access 
Retrospective cohort study evaluating 
clinical, biochemical and 
pharmacological prognostic factors for 
prostate cancer progression using 
primary care data
Samuel William David Merriel   ,1 Suzanne Marie Ingle,2 Margaret T May,2,3 
Richard M Martin2,3
To cite: Merriel SWD, Ingle SM, 
May MT, et al.  Retrospective 
cohort study evaluating 
clinical, biochemical and 
pharmacological prognostic 
factors for prostate cancer 
progression using primary 
care data. BMJ Open 
2021;11:e044420. doi:10.1136/
bmjopen-2020-044420
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 044420).
Received 06 September 2020
Revised 01 February 2021
Accepted 02 February 2021
1College of Medicine & Health, 
University of Exeter, Exeter, UK
2Bristol Medical School, 
Population Health Sciences, 
University of Bristol, Bristol, UK
3National Institute for Health 
Research (NIHR) Biomedical 
Research Centre, University 
Hospitals Bristol NHS Foundation 
Trust and the University of 
Bristol, Bristol, UK
Correspondence to
Dr Samuel William David 
Merriel;  
 s. w. d. merriel@ exeter. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objectives To confirm the association of previously 
reported prognostic factors with future progression of 
localised prostate cancer using primary care data and 
identify new potential prognostic factors for further 
assessment in prognostic model development and 
validation.
Design Retrospective cohort study, employing Cox 
proportional hazards regression controlling for age, 
prostate specific antigen (PSA), and Gleason score, was 
stratified by diagnostic stage.
Setting Primary care in England.
Participants Males with localised prostate cancer 
diagnosedbetween 01/01/1987 and 31/12/2016 within the 
Clinical Practice ResearchDatalink database, with linked 
data from the National Cancer Registration andAnalysis 
Service and Office for National Statistics.
Primary and secondary outcomes Primary outcome 
measure was prostate cancer mortality. Secondary 
outcome measures were all- cause mortality and 
commencing systemic therapy. Up- staging after diagnosis 
was not used as a secondary outcome owing to significant 
missing data.
Results 10 901 men (mean age 74.38±9.03 years) with 
localised prostate cancer were followed up for a mean 
of 14.12 (±6.36) years. 2331 (21.38%) men underwent 
systemic therapy and 3450 (31.65%) died, including 1250 
(11.47%) from prostate cancer. Factors associated with an 
increased risk of prostate cancer mortality included age; 
high PSA; current or ex- smoker; ischaemic heart disease; 
high C reactive protein; high ferritin; low haemoglobin; 
high blood glucose and low albumin.
Conclusions This study identified several new potential 
prognostic factors for prostate cancer progression, as 
well as confirming some known prognostic factors, in an 
independent primary care data set. Further research is 
needed to develop and validate a prognostic model for 
prostate cancer progression.
INTRODUCTION
Prostate cancer prognosis and treatment deci-
sions remain a challenging clinical area for 
clinicians and patients, particularly for men 
with localised disease at the time of diagnosis. 
In recent decades, prostate cancer detec-
tion rates in many countries have increased 
markedly, in part, as a result of the rising use 
of asymptomatic prostate specific antigen 
(PSA) testing;1 however, more intensive PSA- 
based detection of prostate cancer has not 
been convincingly directly correlated with 
reductions in prostate cancer mortality for 
all men,2 implying increasing overdetection 
of clinically insignificant tumours.3 Treat-
ments for prostate cancer carry a significant 
risk of morbidity for men,4 5 underlining the 
importance of being able to identify which 
men with tumours confined to the prostate at 
diagnosis are at higher risk of prostate cancer 
progression and mortality to inform discus-
sions about management options.
Defining and measuring cancer progres-
sion with respect to treatment studies is 
outlined in the Response Evaluation Criteria 
in Solid Tumours (RECIST) criteria, which 
was originally published by the World Health 
Organisation (WHO) in 20006 and most 
recently updated in 2009.7 Evidence of 
tumour shrinkage on imaging and time to 
development of disease progression are used 
to measure treatment response. Definitions 
of cancer progression that are relevant to 
Strengths and limitations of this study
 ► Large retrospective cohort study of men with local-
ised prostate cancer.
 ► Mean follow- up of 14.12 years.
 ► Data available on a wide range of potential prognos-
tic factors for prostate cancer progression.
 ► Missing cancer stage and grade data from National 
Cancer Research and Analysis Service cancer regis-
try excluded a proportion of the cohort.
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prognostic studies are less well defined, and numerous 
clinical, biological and surrogate markers of progression 
have been proposed in various studies. Prostate cancer 
mortality appears to be the logical ultimate endpoint of 
prostate cancer progression, but other measures such as 
development of metastases,8 biochemical recurrence,9 
commencing systemic therapy10 and protein expression11 
have also been reported.
There are a plethora of prognostic factor studies and 
prediction tools for prostate cancer risk12 and prognosis13 
in the published literature. The vast majority are not exter-
nally calibrated or validated, and very few are established 
for use in clinical practice.12 Initiatives such as the MRC 
PROGnosis RESearch Strategy Partnership (PROGRESS) 
partnership highlight the importance of high- quality 
prognostic research to help inform clinical practice14 and 
outline methodologically rigorous approaches to achieve 
this aim.15–17 Developing clinically useful risk- prediction 
rules starts with identifying potentially important prog-
nostic factors, which could be incorporated into a predic-
tion model. The aim of the current study is to confirm 
the association of previously reported prognostic factors 
with future progression of localised prostate cancer using 
primary care data and identify new potential prognostic 
factors for further assessment in prognostic model devel-
opment and validation.
MATERIALS AND METHODS
The protocol for this study has been published previously 
in BMJ Open.18 In summary, we undertook a retrospective 
cohort study using a longitudinal data set of prospec-
tively collected electronic primary care medical records 
from general practices (GPs) in England for the Clinical 
Practice Research Datalink (CPRD).19 This data set was 
linked with cancer registry data from the National Cancer 
Research and Analysis Service (NCRAS)20 and mortality 
data from the Office for National Statistics (ONS).21 Men 
were included if they had a diagnosis of prostate cancer 
entered into their medical record during the 20- year study 
period (01 January 1987—31 December 2016). Localised 
prostate cancer was defined as T1-2/N0/M0 based on 
staging data entered into the NCRAS registry, which is 
determined from a combination of clinical, pathological 
and radiological data.22
Potentially relevant clinical, biochemical and pharma-
cological factors measured in CPRD were identified from 
a review of the existing published literature (See BMJ 
Open protocol paper18 for more information about the 
prognostic factors assessed). The primary outcome of the 
study was prostate cancer mortality. Secondary outcomes 
were all- cause mortality and commencing systemic pros-
tate cancer therapy (a measurable proxy for progres-
sion and metastatic spread of prostate cancer). Surgery, 
radiotherapy and brachytherapy were classified as local-
ised therapy, with chemotherapy, hormone treatments 
(primary or neoadjuvant) and immunotherapy consid-
ered systemic therapy. Mortality outcomes were based 
on primary/immediate cause of death reported in death 
certification information from the ONS and therapy 
outcomes from NCRAS data. In our published protocol,18 
up- staging after diagnosis was proposed as a secondary 
outcome indicating spread of disease; however, this was 
not used in the final analysis as repeat staging was rarely 
recorded in the cancer registry.
Descriptive statistics were used to summarise the basic 
demographic details of the men and the prevalence of 
the preselected putative prognostic factors. Cox propor-
tional hazards regression was used to estimate crude and 
mutually adjusted hazard ratios (with 95% CIs) for pros-
tate cancer- specific and all- cause mortality according to 
the prognostic factors, controlling for variables currently 
used in clinical practice (age, PSA level, Gleason score). 
Regression analyses of continuous prognostic factors 
were standardised using hazard ratios per change in 
one SD. A proportional hazards test was performed to 
confirm modelling met regression assumptions. The anal-
ysis was also stratified by stage at diagnosis (T1/2N0M0 
vs T3+and/or N1 and/or M1). Sensitivity analysis was 
performed, assuming all men in the overall sample with 
unknown tumour location had localised disease. In order 
to achieve 95% power and detect a difference of 0.1 in 
prostate cancer mortality for a binary risk factor using an 
alpha of 0.05, a sample of at least 6046 men with prostate 
cancer would be required, assuming that 10% die over a 
median 10- year follow- up.
RESULTS
A total of 54 500 men within CPRD had a diagnosis of 
prostate cancer entered into their primary care medical 
record during the study period. Baseline participant data 
are shown in table 1. Tumour–node–metastases (TNM) 
staging data from the linked cancer registry were avail-
able for 7646 (14.03%) of the sample population and 
treatment data were available for 22 766 (41.77%) men. 
Missing TNM staging data from the cancer registry were 
lower for men diagnosed in more recent years: there 
were no TNM stage data for men diagnosed before 
1993, rising to 37.2% with TNM stage data (1064/2836) 
in 2015. This is consistent with a recent validation study 
of the NCRAS prostate cancer registry that showed low 
levels of completeness of TNM stage and Gleason score 
data prior to 2010.23 Using the available staging and treat-
ment data, 10 901 (20%) men were identified as having 
localised prostate cancer at the time of diagnosis and 
were included in the final cohort for analysis, with a mean 
follow- up of 14.12 (±6.36) years. Levels of missing data for 
selected prognostic factors within CPRD varied.
1250 men with localised disease died of prostate cancer 
over the course of follow- up, giving a prostate cancer 
mortality rate of 8.1 per 1000 person- years. The total 
number of deaths for included men was 3450 (21.11 
deaths per 1000 person- years). A total of 2331 (21.38%) 
men with localised disease received systemic therapy in 
the follow- up period after diagnosis. For over 90% of the 
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men, it was unknown whether they were reinvestigated 
for cancer staging after diagnosis or not (see table 2).
Raised acute phase reactants (C reactive protein (CRP) 
(adjusted HR per SD 1.35 95% CI 1.02 to 1.77)), ferritin 
(adjusted HR per SD 2.03; 95% CI 1.21 to 3.39) and 
random glucose (adjusted HR per SD 1.27; 95% CI 1.06 
to 1.54) were associated with prostate cancer mortality. 
Anaemia (adjusted HR per SD 0.72; 95% CI 0.59 to 0.88) 
and low albumin (adjusted HR per SD 0.81; 95% CI 0.67 
to 0.97) were also associated with this outcome. No medi-
cations assessed were associated with prostate cancer 
mortality. Current and ex- smokers (adjusted HR 1.47; 
95% CI 1.05 to 2.05) and patients with a history of isch-
aemic heart disease (adjusted HR 1.79; 95% CI 1.20 to 
2.66) had a higher risk of prostate cancer mortality over 
the study period.
Raised CRP, anaemia and low albumin were biochemical 
factors associated with all- cause mortality; with anaemia 
and low albumin also being associated with commencing 
systemic therapy. A number of other factors were also 
associated with all- cause mortality, including age, raised 
PSA, smoking and smoking- related disease, cardiovas-
cular diseases as well as current use of aspirin or beta- 
blockers. Smoking and beta- blockers were also associated 
with increased risk of systemic therapy, as were vitamin 
D supplements. Benign prostatic hyperplasia and alpha- 
blocker prescription were associated with a reduced risk 
of commencing systemic therapy (see tables 3 and 4 for 
adjusted analysis results and online supplemental tables 
S1 and S2 for unadjusted results).
Sensitivity analysis including all participants with 
unknown tumour location showed a relationship between 
a history of stroke and all- cause mortality (adjusted HR 
1.47; 95% CI 1.12 to 1.93 p=0.006). The relationship 
between aspirin and prostate cancer mortality altered 
to very weak evidence for association (adjusted HR 1.55 
95% CI 0.79 to 3.02 p=0.2). For all other factors measured 
and for all three outcomes in the analysis, the direction 
of relationship did not change and the magnitude of rela-
tionship stayed relatively stable (see online supplemental 
tables S3–6).
DISCUSSION
This retrospective cohort study used primary care medical 
records data for men with localised prostate cancer from 
CPRD to confirm prognostic factors associated with pros-
tate cancer progression. Well- known factors already incor-
porated into clinical guidelines, such as age and PSA, 
were confirmed as being individual prognostic factors. 
In addition, further clinical (history of smoking or isch-
aemic heart disease) and biochemical (anaemia or high 
ferritin) factors were found to be strongly associated with 
prostate cancer mortality. Anaemia, low albumin, raised 
PSA, history of ischaemic heart disease and smoking were 
also strongly associated with all- cause mortality, as were 
Table 1 Baseline participant data
 Localised
n=10 901 Missing data
Mean (SD)
  Age (years) 74.38 (±9.03) 0%
  BMI (kg/m2) 27.43 (±4.48) 5.64%
  Follow- up (years) 14.12 (±6.36) 0%
Median (IQR)
  PSA (ng/mL) 8.4 (5.55, 14.6) 30.66%
n (%)
Gleason score
  6 3655 (33.53%) 33.23%
  7+ 4420 (40.55%)




  White 7361 (67.53%) 29.79%
  Mixed 21 (0.19%)
  Asian 75 (0.69%)
  Black 156 (1.43%)
  Other 41 (0.38%)
BMI, body mass index; PSA, prostate specific antigen.
Table 2 Primary and secondary outcomes for included and excluded participants
 

































*Repeat staging data missing for 50 119 (91.96%) of sample.
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peripheral vascular disease, chronic obstructive pulmo-
nary disease and beta- blocker use. Smoking history was 
strongly associated with future systemic therapy, as were 
recent prescriptions of alpha- blockers or vitamin D 
supplements.
This analysis confirms the prognostic associations of 
some factors in prostate cancer progression. Smoking 
has also been found to be a risk factor for prostate 
cancer progression and mortality in cohort studies24 
and systematic reviews.8 Low albumin was associated 
with prostate cancer mortality in the Apolipoprotein- 
related MOrtality RISk (AMORIS) cohort25 and, along 
with anaemia,26 was a more widely accepted predictor 
of poor cancer outcomes.27 The published literature 
around the prognostic effect of beta- blockers for pros-
tate cancer patients has been more mixed,28 with this 
study lending weight to the evidence of increased 
mortality in patients with cancer. Body mass index 
(BMI) was not shown to be associated with prostate 
cancer and overall mortality in this study. While some 
observational studies of prostate cancer have suggested 
that an association may exist,8 29 30 reviews of trial data 
have demonstrated that higher BMI may actually 
improve the prognosis for men with cancer.31
This study attempted to confirm prognostic factors 
in a primary care data set that could be used in a model 
to predict prostate cancer progression at the time of 
diagnosis, prior to any treatment being initiated. This 
approach could allow the identified prognostic factors 
to be used to develop a new prognostic tool to inform 
treatment decisions between a patient and their 
treating team. There are already examples of similar 
prognostic tools available for use, including Predict 
Prostate (https:// prostate. predict. nhs. uk/). However, 
these tools have only been developed using secondary 
care data,32 which may not capture all important prog-
nostic factors or have equivalent length of follow- up of 
patients in their development or calibration cohorts. 
In the context of on- going challenges with prognosti-
cation for men with localised prostate cancer and the 
increasing numbers of men being diagnosed every year, 
getting the most accurate information to inform treat-
ment discussions between patients and their treating 
physicians is vital.
Strengths and limitations
This study has a number of unique features. This is 
the first study that the authors are aware of to use a 
primary care data set to identify and confirm prog-
nostic factors associated with prostate cancer progres-
sion. CPRD contains all data held in the primary care 
records of millions of UK patients, allowing the inclu-
sion of a range of potentially important prognostic 
factors. Using a primary care data set from the National 
Health Service (NHS) also provided long- term data 
for included patients, with a mean follow- up of over 
14 years. Prolonged follow- up for men with prostate 
cancer is important as many patients can live for years 
before their cancer progresses. The lack of high- 
quality prognostic research discussed in the introduc-
tion is not limited to prostate cancer, with many other 
prognostic factor studies being conducted in similarly 
flawed ways.33–35 This study sought to take a confir-
matory approach to postulated prognostic factors in 
prostate cancer in a rigorous manner, following the 
methodological recommendations of the REMARK 
guidelines36 and the PROGRESS partnership.14–17
There are some limitations of this study that need 
to be considered. Previous research has shown that 
the prostate cancer registry in England has strong 
case completeness, but significant missing TNM stage 
and Gleason score data up until recent years.23 Data 
completeness and quality within NCRAS continues to 
improve, and there is no equivalent UK cancer registry 
data set with more complete data available at this 
present time.22 This level of missing data meant that 
it was unknown whether the majority of potentially 
included men had localised disease or not. Even so, 
the study was still powered to answer the research ques-
tion, and sensitivity analyses showed minimal changes 
to almost all relationships between the prognostic 
factors of interest and the study outcomes. Misattribu-
tion of prostate cancer as the primary cause of death 
may occur in some frail, elderly patients or patients 
with multimorbidity, affecting the primary outcome of 
this study. There is evidence of misattribution of pros-
tate cancer as a cause of death in other high- income 
countries;37 38 however, an English study comparing 
death certification to a blinded; independent panel 
showed that ONS data on prostate cancer mortality 
classification are highly accurate.39 This study uses a 
retrospective design interrogating electronic primary 
care records. It relies on accurate coding from GPs,40 
and there was significant missing data for some prog-
nostic factors.
This study took a confirmatory approach to identify 
which prognostic factors for prostate cancer progres-
sion may be relevant, and some new prognostic factors 
not currently recommended for use in clinical practice 
were identified. These prognostic factors could be used 
to generate a more robust clinical risk prediction tool 
to guide treatment decision- making. Developing an 
accurate prediction tool for prostate cancer progres-
sion, not just mortality, could be more useful for 
informing management discussions between patients 
and clinicians.
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